文献速递白血病

利用免疫微环境改善慢性髓性白血病预后

Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.
PubMed 文献 · Leukemia · 2021-04-08

本综述聚焦慢性髓性白血病(CML)患者的免疫失调,以及酪氨酸激酶抑制剂(TKI)和其他治疗在恢复免疫监视中的作用。文章指出免疫监视残留白血病细胞是成功实现无治疗缓解(TFR)的关键因素之一,并探讨了先天免疫、适应性免疫、免疫抑制细胞及免疫调节间充质干细胞等新兴领域,以及供者淋巴细胞输注和干扰素-α等治疗策略在提高TFR率中的潜力。

要点

  • 免疫监视残留白血病细胞是CML实现TFR的关键因素之一。
  • TKI可恢复免疫监视,但免疫失调涉及NK细胞、CTL、MDSC、Treg及MSC等多环节。
  • 供者淋巴细胞输注和干扰素-α等免疫策略有望在TKI时代提升TFR率。

核心结论

  • 深入理解CML免疫微环境对开发新疗法和重新利用旧疗法以提高TFR率至关重要。

研究设计与样本

  • 综述,聚焦新诊断CML患者的免疫失调及TKI和其他治疗对免疫监视的恢复作用。

主要发现

  • 免疫监视残留白血病细胞是成功TFR的关键因素之一,自我更新的白血病干细胞与复发相关。
  • 先天免疫中自然杀伤细胞和浆细胞样树突状细胞是新兴靶点。
  • 适应性免疫中白血病相关抗原疫苗诱导的CD8细胞毒性T细胞(CTL)反应、CTL扩增及免疫检查点抑制剂展现前景。
  • 免疫抑制性髓源性抑制细胞和调节性T细胞在深度分子学缓解(DMR)和TFR中减少。
  • 免疫调节间充质基质细胞通过免疫抑制特性和TKI耐药促进白血病发生。

临床怎么用

  • 供者淋巴细胞输注常与TKI联合用于异基因造血干细胞移植后复发患者。
  • 干扰素-α作为既往标准治疗,在TKI时代后仍有希望实现TFR。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The quest for treatment-free remission (TFR) and deep molecular response (DMR) in chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors (TKIs). Immunologic surveillance of residual leukemic cells is hypothesized to be one of the critical factors in successful TFR, with self-renewing leukemic stem cells implicated in relapse. Immunological characterization in CML may help to develop novel immunotherapies that specifically target residual leukemic cells upon TKI discontinuation to improve TFR rates. This review focuses on immune dysfunction in newly diagnosed CML patients, and the role that TKIs and other therapies have in restoring immune surveillance. Immune dysfunction and immunosurveillance in CML points towards several emerging areas in the key goals of DMR and TFR, including: (1) Aspects of innate immune system, in particular natural killer cells and the newly emerging target plasmacytoid dendritic cells. (2) The adaptive immune system, with promise shown in regard to leukemia-associated antigen vaccine-induced CD8 cytotoxic T-cells (CTL) responses, increased CTL expansion, and immune checkpoint inhibitors. (3) Immune suppressive myeloid-derived suppressor cells and T regulatory cells that are reduced in DMR and TFR. (4) Immunomodulator mesenchymal stromal cells that critically contribute to leukomogenesis through immunosuppressive properties and TKI- resistance. Therapeutic strategies that leverage existing immunological approaches include donor lymphocyte infusions, that continue to be used, often in combination with TKIs, in patients relapsing following allogeneic stem cell transplant. Furthermore, previous standards-of-care, including interferon-α, hold promise in attaining TFR in the post-TKI era. A deeper understanding of the immunological landscape in CML is therefore vital for both the development of novel and the repurposing of older therapies to improve TFR outcomes.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hsieh YC, Kirschner K, Copland M, et al. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia. 2021. PMID: 33833387. doi:10.1038/s41375-021-01238-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。